University of Sydney researchers announced the identification of a distinct "circadian depression" subtype on October 21, 2026, affecting nearly one-quarter of people with severe, recurrent, or persistent depression. This subtype is characterized by specific sleep patterns and genetic markers, responding poorly to traditional antidepressants but well to therapies targeting the body's internal clock.

This discovery could lead to more personalized and effective treatments for many suffering from depression, preventing prolonged ineffective therapies and reducing side effects. Understanding these biological differences means clinicians can provide earlier access to the most effective interventions, especially for young people.

What the records show

This subtype presents with earlier symptom onset, around 18 years old, compared to 23 years for other forms of depression. Participants with circadian depression also experienced more severe clinical features, including mania, psychosis, and higher levels of suicidal thoughts, alongside weight gain during depressive episodes. Genetic analysis indicated a higher genetic risk for conditions such as attention-deficit/hyperactivity disorder (ADHD), major depression, bipolar disorder, and metabolic markers like high body mass index and insulin resistance. Dr. Emiliana Tonini, from the Brain and Mind Centre, stated that this suggests "circadian depression is more than just 'depression with bad sleep.' It involves a mix of metabolic, inflammatory, circadian, and mood-related processes".

Traditional first-line antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), proved less effective and caused more side effects for individuals with this subtype. Conversely, these individuals showed greater responsiveness to behavioral and medical therapies aimed at the body's circadian rhythms, such as melatonin, melatonin-targeted antidepressants, and light therapy. Jacob Crouse noted that treatments targeting the circadian rhythm "may be much more relevant, and clinicians should reach for these much earlier in people with this presentation".

The timeline

What changed and for whom

What the subject has said publicly

Eduard Vieta, Director of the Institute of Neurosciences at Hospital Clínic and Professor of Psychiatry at the University of Barcelona, offered a nuanced perspective. He suggested that describing it as a "new subtype" might be an overstatement, pointing out that the DSM already describes patients with a 'seasonal pattern' and that 'atypical depression' shares many described circadian features. The study authors, however, maintain that their findings support the "biological validity and clinical utility of a circadian subtype of depression as a clinical profile".

What we could not confirm